Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
- HCC - Hepatocellular Carcinoma
- Unresectable Hepatocellular Carcinoma
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- The University of Hong Kong
- Enrolment target
- 30
- Started
- 25 April 2019
- Main results due
- 31 December 2027
- Study sites
- 1
- Registry updated
- 28 September 2026
Can you take part?
- Ages 18 years to 80 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Diagnosis of HCC is made according to American Association for the Study of Liver Diseases (AASLD) practice guideline 2010: patients with cirrhosis of any etiology and patients with chronic hepatitis B (HBV) who may not have fully developed cirrhosis, the presence of liver nodule \>1cm and demonstrated in a single contrast enhanced dynamic imaging \[either computed tomography (CT) or magnetic resonance imaging (MRI)\] of intense arterial uptake and "washout" in portal venous and delayed phases. * Tumor size 5-25 cm or number of lesions ≤3 or segmental portal vein involvement * Age: 18-80 years old * Child Pugh liver function class A-B7 * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 Exclusion Criteria: * Prior invasive malignancy * Prior radiotherapy to the region of liver or selective internal radiotherapy * Severe, active co-morbidity * Presence of extra-hepatic metastases (M1) * Main portal vein or inferior vena cava (IVC) thrombosis or involvement * Presence of ascites or encephalopathy * Contraindicated of SBRT: * Any one hepatocellular carcinoma \> 15 cm * Total maximal sum of hepatocellular carcinoma \> 25 cm * More than 3 discrete hepatic nodule * Direct tumor extension into the stomach, duodenum, small bowel, large bowel, common or main branch of biliary tree
What this study is about
In the sponsor’s own words, from the registry.
Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide and ranks the third on the incidence of cancer-related death. There are more than 500000 new cases diagnosed annually worldwide. The incidence and prevalence of HCC are on rising trend with the majority of the disease burden is in Asia where viral hepatitis B is endemic. Surgical resection, radiofrequency ablation (RFA) and liver transplantation (LT) represent the only chance of cure for HCC patients. Despite more aggressive surgical approach has been adopted in most Asian countries, yet curative intervention remains only amendable in 30% of patients. Most patients are diagnosed with intermediate or advanced stage diseases; the long-term cure rate is only 0-10%. Hence, every effort has been made in an attempt to convert inoperable HCC into operable disease (i.e. downstaging) in order to improve the chance of survival of these patients. The current study, to current knowledge, will be the first study in the field to deploy a novel treatment strategy to deploy both immunotherapy and stereotactic beamed radiotherapy to induce tumor shrinkage rendering it become operable cancer.
Study sites(1)
Queen Mary Hospital
Hong Kong, Hong Kong
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07305428. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me